Microbix Biosystems reports Q1 revenue C$4.22M vs. C$6.04M last year

The company said, “Results for Q1 demonstrated the Company’s efforts to rebuild revenues back above its breakeven point following two client setbacks in mid-2025, with revenue growth of 13% compared to Q4 fiscal 2025. Q1 revenues and net loss were as-budgeted for fiscal 2026…Microbix is prepared for material sales growth following additions to its capabilities and capacity. It is now at work on adding new client programs and clients to counter setbacks with two large clients in 2025. Progress with business development will be announced when secured. Microbix currently anticipates full-year fiscal 2026 results in-line with the forward-looking information disclosed in its Management Discussion and Analysis, towards rebuilding sales above its earnings breakeven point.”